Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

This study has been completed.
Sponsor:
Collaborators:
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Cal Cohen, Community Research Initiative of New England
ClinicalTrials.gov Identifier:
NCT00931801
First received: June 30, 2009
Last updated: March 14, 2013
Last verified: March 2013

June 30, 2009
March 14, 2013
December 2009
February 2012   (final data collection date for primary outcome measure)
Maintenance of Virologic Suppression [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
To evaluate and compare maintenance of virologic suppression with raltegravir (RAL) 400mg 2x daily plus atazanavir (ATV) dosed either as ATV/ritonavir (RTV)300/100mg 1x daily or ATV 300mg 2x daily in subjects with virologic suppression on a standard regimen of ATV/RTV plus Truvada. Virologic suppression is defined as HIV RNA < 40 copies/mL.
To evaluate and compare maintenance of virological suppression to raltegravir 400mg twice daily plus atazanavir twice daily in subjects with virologic suppression on a standard regimen of boosted atazanavir plus tenofovir and emtricitabine [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00931801 on ClinicalTrials.gov Archive Site
  • The Difference in CD4 From Baseline to Week 48 [ Time Frame: Baseline and Week 48 ] [ Designated as safety issue: No ]
    Change in mean CD4 from Baseline to Week 48.
  • The Change in Adherence to Study Treatment Arm From Baseline to Week 48 [ Time Frame: Baseline and Week 48 ] [ Designated as safety issue: No ]
    Adherence to study treatment reported as the percentage of doses of the prescribed treatment arm regimen taken, described by each subject through recall of dosing in the three days prior to the visit Baseline and Week 48 vistis. The change in adherence is reflected as the difference of the mean percentage of adherence per arm between Baseline and Week 48 visits.
  • Change in Quality of Life From Baseline to 48 Weeks of Study Treatment [ Time Frame: baseline and 48 weeks ] [ Designated as safety issue: No ]
    Quality of Life was measured by self report using a standardized scale, where 0 is death and 100 is perfect health. The baseline measure was obtained prior to initiation of study treatment arm. The week 48 measure captures Quality of Life by self report at 48 weeks of study treatment.
  • To evaluate the safety of raltegravir 400mg twice daily in conjunction with atazanavir/ritonavir 300/100mg once daily or atazanavir 300mg twice daily [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
  • To evaluate the tolerability of raltegravir 400mg twice daily in conjunction with atazanavir/ritonavir 300/100mg once daily or atazanavir 300mg twice daily [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • To evaluate satisfaction with the treatment regimen in subjects on raltegravir 400mg twice daily in conjunction with atazanavir/ritonavir 300/100mg once daily or atazanavir 300mg twice daily [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.
A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects With Virologic Suppression on a Standard Regimen of Boosted Atazanavir, Tenofovir and Emtricitabine

The purpose of this Phase IV pilot study is to evaluate the safety, tolerability, and satisfaction of a nucleoside analog reverse-transcriptase inhibitors (NRTI)sparing regimen for participants fully suppressed on an atazanavir/ritonavir based highly active antiretroviral therapy (HAART)regimen plus emtricitabine/tenofovir (Truvada). Several pharmacologic factors support this concept including the favorable drug interaction between atazanavir and raltegravir. Participants will be randomized to either continue on their current regimen or one of two study arms (atazanavir 300mg plus ritonavir 100mg daily plus raltegravir 400mg twice daily or atazanavir 300mg twice daily plus raltegravir 400mg twice daily). Participants will be followed for 48 weeks for safety, tolerability, and satisfaction. After baseline, the participants will have six clinic visits for evaluation and labs.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV
  • Drug: atazanavir/raltegravir
    Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily
  • Drug: atazanavir/raltegravir
    Atazanavir 300mg twice daily plus raltegravir 400mg twice daily
  • Drug: atazanavir/tenofovir/emtricitabine
    Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine
    Other Name: Truvada
  • Experimental: Intervention Arm No.1
    Intervention: Drug: atazanavir/raltegravir
  • Experimental: Intervention Arm No.2
    Intervention: Drug: atazanavir/raltegravir
  • Active Comparator: Control Arm
    Continue baseline regimen
    Intervention: Drug: atazanavir/tenofovir/emtricitabine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
43
March 2012
February 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV-1 infection
  • Treatment with a stable antiretroviral regiment containing boosted atazanavir, tenofovir and emtricitabine at screen and for at least 90 days prior to screening
  • No plan to make changes to HIV treatment regimen (other than those required by the study) in the next 48 weeks
  • Undetectable HIV RNA at screening AND no HIV RNA>200 copies during the 180 day period prior to screening
  • CD4 count>200
  • No evidence of resistance to any of the drugs in any of the 3 arms, if prior resistance tests are available
  • Subjects who, in the opinion of their treating physicians, would be candidates to switch antiretroviral medications
  • Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the last dose of study drug
  • Ability and willingness to provide written informed consent and comply with protocol requirements

Exclusion Criteria:

  • Prior exposure to raltegravir or elvitegravir
  • Women who are pregnant, breast-feeding, or with a positive pregnancy test
  • Sexually active fertile men not using effective birth control if their female partners are of child-bearing potential
  • Women of child-bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of study drug
  • Life expectancy less than 6 months
  • Presence of any currently active AIDS defining conditions with the exception of stable cutaneous Kaposi's sarcoma
  • Treatment with proton-pump inhibitor or H2-receptor antagonist
  • ECG demonstrating atrioventricular block, prolonged QRS interval greater than 12 ms, or known complete bundle branch block
  • Acute or chronic hepatitis B infection as evidenced by presence of hepatitis B surface antigen and absence of hepatitis B surface antibody
  • Clinical or laboratory evidence of significantly decreased hepatic function of decompensation irrespective of liver enzyme levels
  • Prisoners or subjects who are involuntarily incarcerated
  • Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00931801
09-102
Yes
Cal Cohen, Community Research Initiative of New England
Community Research Initiative of New England
  • Bristol-Myers Squibb
  • Merck Sharp & Dohme Corp.
Principal Investigator: Calvin J Cohen, MD, MSc Community Research Initiative
Community Research Initiative of New England
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP